Urology Center of Englewood
Latest Clinical News

Midlife PSA Levels Correlate to Risk of Future Lethal Prostate Cancer (08-15-2016)

A baseline prostate-specific antigen (PSA) level among men at midlife appears to be highly correlated with the risk of developing lethal prostate cancer within their lifetimes. These results were recently published in the Journal of Clinical Oncology. Prostate... Continue Reading

New Tool Helps Men Evaluate Watchful Waiting in Early Stage Prostate Cancer (08-10-2016)

Over 90 percent of prostate cancers are detected at a curable stage, with men more likely to die of other diseases than from this cancer. Although patients with localized, low-risk prostate cancer have treatment options: active surveillance, also called... Continue Reading

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer (07-26-2016)

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published in the Journal of Clinical Oncology. Prostate cancer... Continue Reading

FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer (06-13-2016)

The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent prostate cancer. Prostate cancer is the second... Continue Reading

Tecentriq® Approved for Bladder Cancer (06-8-2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved... Continue Reading

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (06-8-2016)

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (05-25-2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Addition of Radiation Improves Survival in High-Risk Prostate Cancer (05-18-2016)

The addition of radiation therapy to androgen-deprivation therapy among men with prostate cancer who are at a high risk of a cancer recurrence significantly improves long-term survival. These results were recently published in the journal of European... Continue Reading

Chemotherapy After Prostatectomy Delays Cancer Progression in High-Risk Prostate Cancers (05-17-2016)

The use of chemotherapy following a radical prostatectomy delays the time to cancer progression among men with prostate cancer who are at a high risk of developing a recurrence.  These results were recently presented at the 2016 Annual Scientific Meeting... Continue Reading

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer (04-25-2016)

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer.  It is important for patients receiving ADT to speak... Continue Reading

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers (03-14-2016)

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy raise their risk of getting other cancers by nearly... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (02-22-2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

« Previous PageNext Page »